aTyr Pharma counsel vests RSUs, sells 1,118

aTyr Pharma’s general counsel, Nancy Denyes, reported routine equity compensation activity and a small share sale.

Rhea-AI Filing Summary

aTyr Pharma’s general counsel, Nancy Denyes, reported routine equity compensation activity and a small share sale. On February 3, 2026, 2,687 restricted stock units granted in 2022 vested and converted into the same number of common shares. On February 4, 2026, she sold 1,118 shares at $0.9761 per share to cover tax withholding tied to this RSU vesting. After these transactions, she directly owned 33,124 aTyr Pharma common shares.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider DENYES NANCY

Role General Counsel

Sold 1,118 shs ($1K)

Approx. gross sale proceeds $1K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	1,118	$0.9761	$1K
Exercise	Restricted Stock Unit	2,687	$0.00	$0.00
Exercise	Common Stock	2,687	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 33,124 shares (Direct)

Footnotes (4)

1. F1. Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
2. F2. Restricted stock units convert into common stock on a one-for-one basis.
3. F3. Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
4. F4. The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider in this aTyr Pharma (ATYR) Form 4 filing?

The insider is Nancy Denyes, who serves as aTyr Pharma’s General Counsel. The filing reports her equity compensation activity and a related small share sale in early February 2026, all held in her direct ownership.

What share transactions did Nancy Denyes report for aTyr Pharma (ATYR)?

She reported 2,687 shares of common stock acquired on February 3, 2026 through vesting of restricted stock units, and a sale of 1,118 common shares on February 4, 2026 at $0.9761 per share to satisfy tax withholding obligations.

How many aTyr Pharma (ATYR) shares does Nancy Denyes own after these transactions?

After the reported RSU vesting and subsequent sale, Nancy Denyes directly owns 33,124 shares of aTyr Pharma common stock. The derivative position from this particular RSU grant is shown as fully exercised, with no remaining units from that grant.

Why did Nancy Denyes sell 1,118 aTyr Pharma (ATYR) shares?

The 1,118-share sale on February 4, 2026 was made to satisfy tax withholding obligations connected to the partial vesting of restricted stock units granted on February 3, 2022, according to the explanatory footnote in the Form 4 filing.

How do the aTyr Pharma (ATYR) restricted stock units convert in this Form 4?

The restricted stock units convert into aTyr Pharma common stock on a one-for-one basis. In this filing, 2,687 RSUs vested and converted into 2,687 common shares on February 3, 2026, reflecting the compensation structure granted in February 2022.

What is the vesting schedule for the aTyr Pharma (ATYR) RSUs reported?

The RSUs vest in four equal annual installments starting February 3, 2023, and are fully vested by February 3, 2026. They are also subject to accelerated vesting if there is a termination without cause following a change of control of aTyr Pharma.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 07:12 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DENYES NANCY

(Last) (First) (Middle)

10240 SORRENTO VALLEY ROAD

SUITE 300

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		M(1)		2,687	A	(2)	34,242	D
Common Stock	02/04/2026		S(3)		1,118	D	$0.9761	33,124	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	02/03/2026		M			2,687	(4)	(4)	Common Stock	2,687	$0	0	D

Explanation of Responses:

1. Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.

2. Restricted stock units convert into common stock on a one-for-one basis.

3. Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.

4. The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

	/s/ Nancy E. Denyes	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.